OPEN CALLS | EU H2020 COVID-19

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
CALL

Second call for an Expression of Interest for innovative and rapid health-related approaches to respond to COVID-19 and to deliver quick results for society for a higher level of preparedness of health systems.

Call Timeline:

Types of action: Innovation action | Programme: Horizon 2020
Opening date: 19 May 2020
Deadline model:single-stage
Deadline date:11 June 2020 17:00:00 Brussels time
Call ID: H2020-SC1-PHE-CORONAVIRUS-2020-2A

SC1-PHE-CORONAVIRUS-2020-2A: Repurposing of manufacturing for vital medical supplies and equipment.

Scope: Proposals for innovation actions targeted under this topic should address the re-orientation and repurposing of production capacities to meet the urgent needs of our societies for vital medical supplies and equipment.

The scope covers:

  • The repurposing, adaptation and ramp-up of production lines to quickly adjust to new and urgent production needs, notably medical equipment (e.g. personal protective equipment (PPE), ventilators), diagnostic technologies already deployed based on advanced materials and/or biotechnologies, as well as service systems and automated systems of disinfection,
  • Demonstrate flexibility models for the supply chain for the repurposing of production lines and proper risk management in case of disruption of supply chains (or other necessary means for enabling production, such as energy feedstock),
  • Automation technologies that are less dependent on work force present in factories, certification/calibration/accreditation of production lines that have been repurposed or restarted after a shutdown,
  • Qualification of operators/technicians for new/repurposed production lines.

Click here for more information on this call

SC1-PHE-CORONAVIRUS-2020-2B: Medical technologies, Digital tools and Artificial Intelligence (AI) analytics to improve surveillance and care at high Technology Readiness Levels (TRL)

Scope: Innovation Actions of one of the following two categories to:

  1.  Support solutions that are close-to-market (TRL 7) in one of the COVID-19 areas mentioned below and that have already received, or are about to receive, the CE marking to proceed to large scale testing, piloting and deployment operations in critical healthcare areas (or wherever else is relevant) (type 1);
  2. Support market innovation (from lab-to-fab) for further developing and maturing innovative solutions that have already been validated in lab environments (TRL 6-7 or higher) with the aim to help accelerate developments and achieve conformity assessment (CE marking) (type 2).

Click here for more information on this call

SC1-PHE-CORONAVIRUS-2020-2C: Behavioural, social and economic impacts of the outbreak response 

Scope:  Proposals should focus on lessons learnt: they should i) address how to mitigate social and economic impacts of the outbreak response related to health systems; ii) identify non-intended consequences of epidemic-control decisions; and iii) provide answers to social, including gendered, dynamics of the outbreak and the related public health response. Proposals should analyse the effects and efficiency of these responses (including resilience factors), democratic governance, multi-level cooperation, the critical gaps and the various exit strategies, their underlying methodologies and regional adaptations. Proposals are expected to develop guidelines and best ‘next practices’, and implement interventions to mitigate impacts and boost wellbeing.

Click here for more information on this call

SC1-PHE-CORONAVIRUS-2020-2D: Pan-European COVID-19 cohorts 

Specific Challenge: The COVID-19 pandemic created an urgent demand for evidence-based innovative and rapid solutions to deal with health and health-related emergencies, to offer the best possible care to patients, and to protect the general population and the frontline health care staff. This expression of interest is to complement research efforts in the fight against the coronavirus, in particular projects resulting from the first H2020 expression of interest, which is currently addressing epidemiology and modelling, diagnostics, treatment, and vaccine. In parallel, Research and Innovation should without delay start analysing the lessons from the present crisis, in particular its impact on health and socio-economic aspects, and propose recommendations for being better prepared in the future if confronted with similar events.

Proposals submitted under this expression of interest are expected to establish new and/or build on existing large-scale cohorts to rapidly advance the knowledge on the control of the SARS-CoV-2 infection, develop evidence-based recommendations for effective prevention of the spreading, protection of the population in the coming months/years, and optimized treatment of the COVID-19 patients. The population-based cohorts should also inform on longer-term consequences of COVID-19 on health and well-being of individuals.

Click here for more information on this call

SC1-PHE-CORONAVIRUS-2020-2E: Networking of existing EU and international cohorts of relevance to COVID-19 

Scope: Proposals under this coordination and support action should support the international networking of existing, mainly longitudinal, cohorts in order to extract jointly agreed standardized data on COVID-19 diagnosed/serotyped and matched non-infected individuals. This effort should contribute to help in the identification of key factors influencing the susceptibility to infection and clinical manifestation, to assess the optimized therapeutic and clinical management options, and to derive lessons on the health and socio-economic impacts of the pandemic. They should develop cohort readiness to adapt rapidly to future crisis. Proposals should consider strategies to interact with the COVID-19 cohort(s) that will be funded under this expression of interest and international initiatives on cohorts, as well as liaising with the network of clinical trials on COVID-19.

The Commission considers that proposals requesting a contribution from the EU of between EUR 2 and 3 million would allow these specific challenges to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

Click here for more information on this call

_______________________________

Contact us for any further clarity on these calls.

Further Reading: EC Europa

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp